Alto Neuroscience Inc. has announced the upcoming initiation of a Phase 2b clinical trial for their drug ALTO-207, expected to start by mid-2026. ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to achieve rapid antidepressant effects in patients with treatment-resistant depression $(TRD.UK)$ while mitigating adverse events associated with pramipexole alone. This trial follows the publication of results from the PAX-D study in The Lancet Psychiatry, which demonstrated significant symptom reduction in TRD patients using pramipexole, though accompanied by a high rate of adverse effects. Alto plans to collaborate with the National Health Service and PAX-D clinical sites for the trial. The study results have already been presented during an investor conference call by Alto Neuroscience.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.